Haemonetics (NYSE: HAE) Price Target Raised Amid Strong Performance
Key points
- BTIG analyst Marie Thibault has raised the price target for Haemonetics to $142.00, indicating a potential 16.5% upside from the current share price.
- The company reported strong financial results, with adjusted earnings reaching $1.35 per share and revenue climbing to $357.76 million, both surpassing analyst expectations.
- Haemonetics shares have demonstrated significant market outperformance, rising 25.3% over the past month and 59.00% year-to-date, exceeding sector and industry benchmarks.
Haemonetics (NYSE: HAE) makes products used to collect blood and plasma and support hospital procedures. BTIG analyst Marie Thibault raises its price target to $142.00. At the $121.89 share price cited with the announcement, that target is about 16.5% higher. A price target is an analyst’s estimate, not a guaranteed future price.
The new target follows a strong run for Haemonetics. Shares rise 25.3% over the past month and 59.00% year to date, as highlighted by Zacks Investment Research. That year-to-date gain exceeds the Zacks Medical sector’s 11.4% rise, while the Medical–Products industry is down 10.9%.
Haemonetics’ recent results provide context for the target. Adjusted earnings reach $1.35 per share for the quarter ended September 2026, above the $1.30 analyst estimate and up from $1.27 a year earlier. Revenue rises to $357.76 million from $327.32 million, beating estimates by 3.15%, as highlighted by Zacks Investment Research.
Haemonetics beats analyst estimates for both earnings and revenue in each of the past four quarters. Analysts expect earnings of $5.29 per share for the current fiscal year, a 6.65% increase. These estimates help explain what investors may weigh against Thibault’s $142.00 target.
Read the rest, free
Pop in your email to read every article in full and search any company. It takes five seconds.
You'll get Gro's newsletter too. Leave any time in one click.
